What is IRulya Therapeutics Inc. (QNCX)'s fair-value range?

EvidInvest reads IRulya Therapeutics Inc. (QNCX)'s market price back into the assumptions behind it — the implied P/E, growth rate and cash yield — using its latest filed financials, then lets you set your own. See the full DCF, Graham number, EPV and multiple-based methods at https://evidinvest.com/valuation/QNCX.

How is IRulya Therapeutics Inc. (QNCX)'s fair value calculated?

IRulya Therapeutics Inc. (QNCX)'s fair value is computed with several independent methods — a discounted cash flow (DCF) model, the Graham number, earnings power value (EPV), and valuation multiples such as PE and EV/EBITDA — using data from SEC filings. P/B is optional for non-financial companies and included in the preset range for financial sectors.

Which filing are IRulya Therapeutics Inc. (QNCX)'s valuation inputs based on?

Inputs come from the FY2025 10-K filed 2026-04-10 (accession 0001193125-26-151364). Source: https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/

Fair value · IRulya Therapeutics Inc. (QNCX) · updated 2026-10-29 · from 10-K FY2025

IRulya Therapeutics trades at $31.73. That price implies a P/E of 0.2×.

Name: IRulya Therapeutics Inc. (QNCX) valuation inputs and fair-value methods
Creator: EvidInvest
License: https://evidinvest.com/subscription-terms

Cboe · delayed 15 min · as of 06:21 ET

Are those assumptions reasonable? Use QNCX’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.

What the price implies

P/E: 0.2×

Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 06:21 ET.

Set your own assumptions ↓See how each method got its number Check another stock

Inputs come from the FY2025 10-K filed 2026-04-10 (accession 0001193125-26-151364); set your own on the sliders below. Research, not investment advice.

The filing behind these numbers

IRulya Therapeutics Inc.

Revenue: $0
Diluted EPS: $-33.60
Free cash flow: $-41.8M; operating cash flow − capital expenditure
Diluted shares: 2.5M; weighted average

10-K FY2025 · fiscal year ended 2025-12-31 · filed 2026-04-10 · accession 0001193125-26-151364

Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q2 FY2026 (filed 2026-08-14).

Open this filing on sec.gov

Valuation tool: build your own QNCX range

Fair Value Summary

Daily Price — QNCX

$31.73 -90.8% (1Y)

Your range0 of 7 methods

At least two methods need a usable value to draw a range with these inputs.

Range with preset inputs

$2.14 – $2.14

Price $31.73

Bear $2.14Base $2.14Bull $2.14

The two ranges are identical because every input sits on a preset.

We don’t tell you what QNCX is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has QNCX’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.

Discounted cash flow

N/A

No revenue in the latest annual filing

Preset inputs — revenue-driven DCF from the latest filing

• No revenue in the latest annual filing

Implied by today’s price

Starting free cash flow is not positive; the model has nothing to grow, so no growth rate reaches the price.

Not solvable from the price — Starting free cash flow is not positive; the model has nothing to grow, so no growth rate reaches the price. Showing preset inputs.

This method has no key input to read out of the price. The others below do, and you set them yourself: the growth matrix shows what QNCX has actually filed, and the AI chat will reason it through with you.

Your inputs

Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.

Stage-1 growth5.0%

Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.

-20.0%60.0%

Stage-1 years5 yrs

How long stage-1 growth lasts.

1 yrs10 yrs

Stage-2 growth2.5%

Slower growth after stage 1, before the terminal phase.

-20.0%30.0%

Stage-2 years5 yrs

0 yrs10 yrs

Terminal growth2.5%

Growth forever after the two stages. Above ~3% is rarely justified.

0.0%5.0%

Discount rate (WACC)12.90%

The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.

3.00%15.00%

Net debt ($M)Debt minus cash, from the balance sheet. Subtracted from enterprise value.

Starting FCF ($M)Latest free cash flow from the filing (operating cash flow minus capex).

Shares (M)Diluted shares, from the filing.

Year by year (two-stage model, $M)

PV explicit $-280M · PV terminal $-178M · EV $-458M · equity $-453M

Year	Stage	FCF	Present value
1	Stage 1	$-44M	$-39M
2	Stage 1	$-46M	$-36M
3	Stage 1	$-49M	$-34M
4	Stage 1	$-51M	$-31M
5	Stage 1	$-54M	$-29M
6	Stage 2	$-55M	$-27M
7	Stage 2	$-56M	$-24M
8	Stage 2	$-58M	$-22M
9	Stage 2	$-59M	$-20M
10	Stage 2	$-61M	$-18M

Inputs from the filing

Free cash flow: $-47.0M; sum of the last four quarters
EBIT: $-58.1M; latest annual
Shares: 6.1M
Total debt: $445000
Cash: $5.8M
Net debt: $-5.4M; debt − cash

10-K FY2025 · period ended 2025-12-31 · filed 2026-04-10 · accession 0001193125-26-151364 · sec.gov

Prefer a blank slate with reverse DCF? Open the standalone DCF / reverse DCF for QNCX

Loading history...

Download the full QNCX valuation report (PDF) — free

DCF fair value, Graham number, EPV, key multiples and growth rates in one clean PDF.

IRulya Therapeutics trades at $31.73. That price implies a P/E of 0.2×.

The filing behind these numbers

Valuation tool: build your own QNCX range

Daily Price — QNCX

Your range0 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on QNCX

Compare with peers

Explore

Valuation tool: build your own QNCX range

Daily Price — QNCX

Your range0 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on QNCX

Compare with peers

Explore